



## ORIGINALES

## Antibiotic prescription patterns in Spanish cystic fibrosis patients: results from a national multicenter study

Juan de Dios Caballero<sup>1,2</sup>, Rosa Girón<sup>3,4</sup>, Rosa del Campo<sup>1,2</sup>, Concepción Prados<sup>4,5</sup>, María-Isabel Barrio<sup>5</sup>, Antonio Salcedo<sup>6</sup>, Rafael Cantón<sup>\*1,2</sup> and the GEIFQ (Grupo Español para el Estudio de la Colonización/Infección Broncopulmonar en Fibrosis Quística)<sup>7</sup>

<sup>1</sup>Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigaciones Sanitarias, Madrid, Spain. <sup>2</sup>Red Española de Investigación en Patología Infecciosa (REIPI), Madrid, Spain. <sup>3</sup>Unidad de Fibrosis Quística, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. <sup>4</sup>CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. <sup>5</sup>Unidad de Fibrosis Quística de adultos e infantil, Servicio de Neumología, Hospital Universitario La Paz, Madrid, España. <sup>6</sup>Unidad de Fibrosis Quística Interhospitalaria Niño Jesús-Gregorio Marañón, Madrid, España. <sup>7</sup>See the Acknowledgements.

### Abstract

**Objective:** Information about antibiotic prescription patterns for cystic fibrosis (CF) patients and, specifically, about inhaled treatment strategies for their management is lacking in Spain due to the absence of a national patient registry. In this study we present data about antibiotic prescription in the Spanish CF context that were obtained in a multicenter study, being inhaled treatment strategies the special focus of this work.

**Methods:** Twenty-four specialized CF units (12 adult, 12 pediatric) from 17 tertiary-care hospitals covering all Spanish Autonomous Communities provided sputa and clinical data from 15 consecutive patients. Data about antibiotic and non-antibiotic therapies prescribed to these patients during the year prior inclusion (2013) were retrospectively collected.

**Results:** The multicenter study included 341 CF patients from all age groups and clinical status. The prevalence of oral, inhaled and intravenous therapies was 89% (n = 302), 80% (n = 273) and 31% (n = 105), respectively. The most prevalent oral agents were ciprofloxacin (n = 177, 59%), cotrimoxazole (n = 109, 36%) and amoxicillin-clavulanate (n = 99, 33%), whereas ceftazidime (n = 53, 50%), to-

### Patrones de prescripción de antimicrobianos en pacientes españoles con fibrosis quística: resultados de un estudio multicéntrico nacional

#### Resumen

**Objetivos:** Existen actualmente pocos datos acerca de las pautas de tratamiento antimicrobiano administradas a los pacientes con fibrosis quística (FQ) en España, sobre todo en lo que se refiere a la antibioterapia inhalada. Esta escasez de conocimiento se debe principalmente a la ausencia de un registro nacional de datos de pacientes. En 2013 se llevó a cabo el primer estudio multicéntrico español focalizado en la microbiología de la FQ. En este trabajo presentamos los patrones de prescripción de antimicrobianos administrados durante un año a los pacientes incluidos en dicho estudio.

**Métodos:** Se contó con la participación de 24 unidades de FQ (12 de adultos y 12 de pediatría) procedentes de 17 hospitales españoles. Cada unidad reclutó a 15 pacientes de manera consecutiva, que aportaron muestras respiratorias y datos clínicos. Se recogieron de manera retrospectiva los tratamientos antibióticos y no antibióticos administrados a estos pacientes durante el año previo a su inclusión en el estudio.

**Resultados:** Se incluyeron 341 pacientes con FQ de todos los rangos de edad y de gravedad clínica. La prevalencia de antibioterapia oral, inhalada e intravenosa fue del 89% (n = 302), 80% (n = 273) y 31% (n = 105), respectivamente. Los fármacos administrados con mayor frecuencia por vía oral fueron ciprofloxacino (n = 177, 59%), cotrimoxazol (n = 109, 36%) y amoxicilina-cla-

\* Autor para correspondencia.

Correo electrónico: rafael.canton@salud.madrid.org (Rafael Cantón Moreno).

Recibido el 2 de enero de 2017; aceptado el 19 de febrero de 2017.

DOI: 10.7399/fh.2017.41.3.10746



Los artículos publicados en esta revista se distribuyen con la licencia:  
Artículos published in this journal are licensed with a:  
[Creative Commons Attribution 4.0.](https://creativecommons.org/licenses/by-nc-nd/4.0/)

<https://creativecommons.org/licenses/by-nc-nd/4.0/>

La revista Farmacia Hospitalaria no cobra tasas por el envío de trabajos, ni tampoco cuotas por la publicación de sus artículos.

bramycin (n = 43, 41%) and meropenem (n = 41, 49%) were the most prevalent intravenous ones. Two or more different inhaled antibiotics were administered to 67 patients (24%), 51 of them receiving 2 drugs continuously in alternating schemes. Nebulization of intravenous specific antibiotics was common (n = 39) and, in some cases, was used for maintenance purposes.

**Conclusions:** These results show that the treatment of CF patients is evolving more rapidly than clinical consensus guidelines. Clinical trials evaluating new specific inhaled combinations and new alternative treatment regimes of the existing ones are needed.

#### KEYWORDS

Cystic fibrosis; Antibiotics; Inhaled therapies; Spain

Farm Hosp. 2017;41(3):391-400

## Contribution to scientific literature

This work provides information about the prescription of antimicrobials in the real clinical practice in Spain, beyond the recommendations included in the clinical guidelines that, in general, are based solely on the management of the patient colonized by *Pseudomonas aeruginosa*.

Faculty staff treating cystic fibrosis patients can use this work to know alternative treatment regimens used in Spain for the management not only of *P. aeruginosa* colonized patients but also of those colonized by other important pathogens such as *Burkholderia cepacia* or methicillin-resistant *Staphylococcus aureus*, for which there is no published expert recommendation.

## Introduction

Antibiotic treatment against chronic bronchopulmonary infection in cystic fibrosis (CF) patients has substantially contributed to a rise in their life expectancy over the last years, as well as to an improvement in their quality of life<sup>1,2</sup>. Inhaled antibiotics, in particular, have become the treatment cornerstone of CF patients chronically colonized by *Pseudomonas aeruginosa* due to their contribution to patients' lung function preservation and to the reduction in the number of exacerbations<sup>3-5</sup>.

Antibiotic management in CF patients is, however, very complex. Antimicrobial agents do not often achieve effective concentrations in the lungs due to a higher clearance in these patients. Moreover, they may be ineffective due to the special environment found in the CF lung and to the biofilm-forming ability of CF pathogens; potentially allowing the development of antibiotic resistance<sup>3</sup>. Inhaled agents partially address these problems, but patients can become refractory to them with continuous treatment or lose their benefits during

vulánico (n = 99, 33%), siendo ceftazidima (n = 53, 50%), tobramicina (n = 43, 41%) y meropenem (n = 41, 49%) los más frecuentes por vía intravenosa. Se administraron dos o más antibióticos por vía inhalada a 67 pacientes (24%), habiendo recibido 51 de ellos 2 antibióticos simultáneamente de manera rotatoria. La nebulización de antibióticos con formulación intravenosa fue una práctica común (n = 39) y, en algunos casos, se utilizó durante un tiempo prolongado como terapia de mantenimiento. **Conclusiones:** Los esquemas de tratamiento observados en este estudio demuestran que la terapia antibiótica de la FQ evoluciona más rápidamente que las recomendaciones reflejadas en las guías clínicas. Es necesario evaluar estos nuevos esquemas con estudios clínicos, así como con otros fármacos inhalados de reciente aparición y su papel en los esquemas existentes.

#### PALABRAS CLAVE

Fibrosis quística; Antibióticos; Tratamiento inhalado; España

Farm Hosp. 2017;41(3):391-400

the resting periods of the *on-off* cycles<sup>6-8</sup>. Finally, the emerging role of new CF pathogens, such as *Burkholderia cepacia* complex (BCC), non-tuberculous mycobacteria (NTM) or methicillin-resistant *Staphylococcus aureus* (MRSA), in disease progression has made necessary for physicians to test new treatment strategies against them<sup>2,9,10</sup>.

Thus, antibiotic prescription by CF specialists in "real life" does not always follow the recommendations within consensus guidelines or in drug datasheets. A recent report based on the Cystic Fibrosis Foundation (CFF) Patient Registry data found that CF specialists often prescribe two different inhaled antibiotics in rotational cycles of 28 days to patients chronically colonized by *P. aeruginosa*<sup>11</sup>. Also, many case reports describe the use of intravenous-specific antibiotics by the inhaled route against CF pathogens other than *P. aeruginosa* (or against *P. aeruginosa* strains refractory to conventional therapies), in an attempt to obtain the same benefits that this type of therapy achieves against the bacteria<sup>12</sup>.

In Spain there is no national patient registry, although some information about inhaled antibiotic prescription in our country has been published in the European Cystic Fibrosis Society (ECFS) patient registry<sup>13</sup>. However, the amount of information is scarce and nothing has been reported about treatment regimens, type of antimicrobial agents, etc. Between March to November 2013, we performed a national multicenter study involving the most important CF-specialized units which represented all the different Autonomous Communities in Spain<sup>14</sup>. Our objectives were not only to determine the Spanish CF pathogens epidemiology, but also to describe the clinical and demographical characteristics of our CF population in the context of an absence of a national registry. In this work, we present the prevalence of the different antibiotic and non-antibiotic therapies administered to these patients in the year prior to their inclusion in the

study (2013), with a special focus on the type and mode of administration of inhaled antibiotics.

### Methods

The methodology of this prospective, multicenter, observational study has already been published<sup>14</sup>. Briefly, 24 specialized CF Units for adult (n=12) and pediatric (n=12) patients in 17 Spanish tertiary-care hospitals participated, providing sputum samples and clinical and demographical data from 15 non-selected consecutive patients during their routine follow-up visits. Patients' data collection included antibiotic therapies prescribed during the year before the recruitment, as well as the use of azithromycin as anti-inflammatory drug and other non-antibiotic therapies like aerosolized hypertonic saline (HS) or dornase alpha (Dα). Antibiotic prescription was also stratified by age (<18 and ≥18 years old, respectively), by pulmonary function measured by the last FEV<sub>1</sub> before inclusion (mild disease: ≥70% and moderate-severe disease: <70%) and by *P. aeruginosa* colonization status (chronic, intermittent or absent) following the modified Leeds criteria<sup>15</sup>. Proportional Venn and linear diagrams were generated by on-line applets (<http://www.eulerdiagrams.org/eulerAPE>; <https://www.cs.kent.ac.uk/people/staff/pjr/linear/>)<sup>16,17</sup>. The study was approved by each participant hospital's ethical committee. Written informed consent was provided by all patients and/or by their parents or legal guardians.

### Results

Three hundred and forty-one patients were recruited in the multicenter study and their clinical and demographical characteristics have already been published but they are also summarized in Table 1<sup>14</sup>. *P. aeruginosa* colonization status was defined as chronic, intermittent or

absent in 158 (46%), 74 (22%) and 109 (32%) patients, respectively. The corresponding numbers for patients <18 years (n=161) were 46 (29%), 41 (25%) and 74 (46%), and for patients ≥18 years (n=180) were 112 (63%), 33 (18%) and 35 (19%), respectively. Nearly all the patients (n=338, 99%) received some type of antibiotic during the year prior to their inclusion in the study (Table 2) and the prevalence of oral, inhaled and intravenous therapies was 89% (n=302), 80% (n=273) and 31% (n=105), respectively. The proportion of patients in whom oral, inhaled and intravenous administration routes were combined is shown in Figure 1. The corresponding diagrams for patients stratified by age, pulmonary function and *P. aeruginosa* colonization status are shown in Figures 2-4.


The most frequent oral agents administered to the patients included ciprofloxacin (59%), trimethoprim-sulfamethoxazole (36%) and amoxicillin-clavulanate (33%). The most prevalent intravenous treatments were ceftazidime (50%), tobramycin (41%), meropenem (39%) and piperacillin-tazobactam (26%) (Table 2). Inhaled and intravenous antibiotics were significantly more often prescribed to patients aged ≥18 years (p<0.001), with *P. aeruginosa* chronic colonization (p<0.001) and with moderate-advanced disease (p<0.001), and also oral antibiotics were significantly more often prescribed in the last two groups (p=0.006 and p=0.04, respectively).

As to the inhaled antibiotic therapies, the majority of the patients (n=206, 76%) received only one inhaled antibiotic, whereas two or three different inhaled antibiotics were administered in 61 (22%) and 6 (2%) patients, respectively (Figure 5). Among these 67 patients in whom more than one inhaled antibiotic was prescribed,

**Table 1.** Clinical and demographical characteristics of the patients

<b>Number of patients</b>	<b>341</b>
<b>Females, no. (%)</b>	<b>180 (53)</b>
<b>Age (years)</b>	
Mean (SD)	21 (11)
Range	2 - 56
≥ 18 years, no. (%)	180 (53)
<b>Mean (SD) FEV<sub>1</sub> (%)<sup>A</sup></b>	<b>68 (25)</b>
FEV <sub>1</sub> in < 18 years <sup>B</sup>	79 (23)
FEV <sub>1</sub> in ≥ 18 years <sup>C</sup>	58 (23)
<b>Pulmonary exacerbations, median [p25;p75]<sup>D</sup></b>	<b>2 [4;1]</b>
<b>Hospitalization events, no. (%)<sup>E</sup></b>	<b>97 (29)</b>
Mean (SD) number of events	1.6 (0.9)
Mean (SD) hospitalization days	24 (35)

Data available for: A: 330 patients; B: 150 patients; C: 180 patients; D: 312 patients; E: 337 patients.




**Figure 1.** Area proportional Venn diagram showing the annual prevalence of prescribed antibiotics by their administration route. The 3 ellipses correspond to the prevalence of oral (yellow), inhaled (blue) and intravenous (red) therapies administered to our patients in a one-year period. Overlapping areas identify patients receiving antibiotics by more than 1 administration route.


**Table 2.** Antibiotic therapies administered to the patients in a one-year period

Antibiotics	N° (%) of patients by therapy's route of administration		
	Oral, 302 (89)	Inhaled, 273 (80)	Intravenous, 105 (31)
<b>β-lactams</b>	<b>134 (44)</b>	<b>44 (17)</b>	<b>99 (94)</b>
Ampicillin	5 (1.7)	9 (3)	-
Amoxicillin-clavulanate	99 (33)	-	4 (4)
Piperacillin-tazobactam	-	-	27 (26)
Cefuroxime	41 (14)	-	-
Ceftazidime	-	15 (5)	53 (50)
Imipenem	-	1 (0.4)	8 (8)
Meropenem	-	-	41 (39)
Aztreonam	-	22 (8)	-
Other β-lactams	9 (3) <sup>A</sup>	-	8 (8) <sup>B</sup>
<b>Aminoglycosides</b>	<b>-</b>	<b>103 (38)</b>	<b>68 (65)</b>
Gentamicin	-	3 (1)	3 (3)
Tobramycin	-	90 (33)	43 (41)
Amikacin	-	11 (4)	27 (26)
<b>Quinolones</b>	<b>207 (69)</b>	<b>-</b>	<b>7 (7)</b>
Ciprofloxacin	177 (59)	-	3 (3)
Levofloxacin	48 (16)	-	4 (4)
Moxifloxacin	3 (1)	-	-
<b>Colistin</b>	<b>-</b>	<b>186 (68)</b>	<b>8 (8)</b>
<b>Tetracyclines</b>	<b>19 (6)<sup>C</sup></b>	<b>-</b>	<b>1 (1)<sup>D</sup></b>
<b>Glycopeptides</b>	<b>-</b>	<b>9 (3)</b>	<b>11 (11)</b>
Vancomycin	-	9 (3)	8 (8)
Teicoplanin	-	-	4 (4)
<b>Linezolid</b>	<b>22 (7)</b>	<b>-</b>	<b>3 (3)</b>
<b>Trimethoprim-sulfamethoxazole</b>	<b>109 (36)</b>	<b>-</b>	<b>2 (2)</b>
<b>Other antibiotics</b>	<b>11 (4)<sup>E</sup></b>	<b>-</b>	<b>-</b>
<b>Antifungal agents</b>	<b>23 (8)<sup>F</sup></b>	<b>1 (0.4)<sup>G</sup></b>	<b>1 (1)<sup>G</sup></b>


A: Cefditoren (n=3), cefadroxil (n=1), cefaclor (n=2); cloxacillin (n=3); B: Cefoxitin (n=2), cloxacillin (n=2); cefepime (n=4); C: Doxycycline (n=4), minocycline (n=15); D: Tigecycline (n=1); E: Rifampicin (n=6); fusidic acid (n=2), metronidazole (n=1), fosfomicin (n=2), clindamycin (n=1); F: Itraconazole (n=14), voriconazole (n=9), fluconazole (n=1); G: Amphotericin B (n=1). Some patients received more than one oral, intravenous or inhaled antibiotic, which explains why the percentages of each group of antimicrobials (e.g. β-lactams) are not equal to the addition of the frequencies of each individual agent.



**Figure 2.** Area proportional Venn diagram showing the annual prevalence of prescribed antibiotics by its administration route among patients stratified by their age. The 3 ellipses correspond to the prevalence of oral (yellow), inhaled (blue) and intravenous (red) therapies administered to our patients in a one-year period. Overlapping areas identify patients receiving antibiotics by more than 1 administration route.



**Figure 3.** Area proportional Venn diagram showing the annual prevalence of prescribed antibiotics by its administration route among patients stratified by their pulmonary function ( $FEV_1 \geq 70\%$ =mild disease;  $FEV_1 < 70\%$ =moderate-severe disease). The 3 ellipses correspond to the prevalence of oral (yellow), inhaled (blue) and intravenous (red) therapies administered to our patients in a one-year period. Overlapping areas identify patients receiving antibiotics by more than 1 administration route.




**Figure 4.** Area proportional Venn diagram showing the annual prevalence of prescribed antibiotics by its administration route among patients stratified by their *P. aeruginosa* colonization status. The 3 ellipses correspond to the prevalence of oral (yellow), inhaled (blue) and intravenous (red) therapies administered to our patients in a one-year period. Overlapping areas identify patients receiving antibiotics by more than 1 administration route.



**Figure 5.** Length proportional linear diagram showing the annual prevalence of all the antibiotics prescribed to CF-patients by an inhaled route. Each antibiotic is represented by a horizontal bar. Areas in which lines overlap (depicted in white and pink) represent patients receiving more than one inhaled antibiotic. Numbers up and down the figure represent patients that received one or more inhaled treatments in the year 2013, being in red those taking only one antibiotic, in black those taking two antibiotics and in blue those taking 3 antibiotics. AMK: amikacin; AMP: ampicillin; AZLI: aztreonam-lysine; CAZ: ceftazidime; COL: colistin; GEN: gentamicin; TOB: tobramycin; VAN: vancomycin.

51(19%) received two antimicrobials concomitantly in a rotating scheme, whereas 5 did not alternate the treatments and no information was available for 11 patients. The prescription prevalence of the three approved inhaled antibiotics in Spain (sodium colistimethate, tobramycin and aztreonam lysine) is shown in Figure 6. Although liposomal amikacin was not approved in our country at the time of the study, it was received by 8 patients in monotherapy as part of a clinical trial. Interestingly, there was a high percentage of patients (14%, n=39) who received intravenous-formulated antibiotics by inhalation, the most frequent of them being ceftazidime (n=15, 5%), ampicillin (n=9, 3%) and vancomycin (n=9, 3%). The administration of intravenous-specific antibiotic formulations by the inhaled route and the pathogens associated with these treatment schemes are summarized in Table 3.

Anti-inflammatory azithromycin administered orally to 198 (58%) patients in the year prior to their recruitment was significantly higher among those aged  $\geq 18$  years ( $p < 0.001$ ), with *P. aeruginosa* chronic colonization ( $p < 0.001$ ) and with moderate-advanced disease ( $p < 0.001$ ). The prevalence of other non-antibiotic therapies is shown on Table 4. No significant differences were seen in HS administration between patient groups, whereas D $\alpha$  administration was significantly higher in patients with moderate-severe disease vs. patients with mild disease ( $p = 0.004$ ). Bronchodilators (BD) and inhaled glucocorticoids (IGC) were significantly given more



**Figure 6.** Area proportional Venn diagram showing the annual prescription prevalence of the currently approved inhaled antibiotics in Spain. Overlapping areas identify patients receiving more than one class of inhaled antibiotic in the year prior to their inclusion in the study. **A:** Some patients in this group also received inhaled amikacin (n=2), ampicillin (n=3), ceftazidime (n=1), vancomycin (n=5) and gentamicin plus ceftazidime (n=1). **B:** A patient in this group also received inhaled ampicillin. **C:** Some patients in this group also received inhaled ampicillin (n=1) and ceftazidime (n=1). **D:** Some patients in this group also received inhaled amikacin (n=1) and vancomycin (n=2).

to patients aged  $\geq 18$  years ( $p < 0.001$ ) and to patients with moderate-advanced disease ( $p < 0.001$ ) and no differences in their use were seen when considering the *P. aeruginosa* colonization status of the patients.

**Table 3.** Number of patients treated with inhaled intravenous-specific formulations and their targeted CF pathogens

Antibiotic	Other inhaled associations	No. of patients	Associated CF pathogen
Amikacin*	None	2	<i>Mycobacterium abscessus</i>
	COL <sup>C</sup>	1	
Ampicillin	None	5	Methicillin-susceptible <i>Staphylococcus aureus</i>
	COL <sup>C</sup>	3	
	AZLI <sup>C</sup>	1	
Ceftazidime	None	11	<i>Burkholderia cepacia</i> complex (n=13) <i>Achromobacter xylosoxidans</i> (n=2)
	COL <sup>U</sup>	1	
	AZLI <sup>U</sup>	1	
	COL + AZLI <sup>S</sup>	1	
	COL + GEN <sup>S</sup>	1	
Imipenem	None	1	<i>Bordetella bronchiseptica</i>
Gentamicin	None	2	Methicillin-resistant <i>S. aureus</i>
	COL + CAZ <sup>S</sup>	1	
Vancomycin	None	2	Methicillin-resistant <i>S. aureus</i>
	COL <sup>C</sup>	5	
	TOB <sup>U</sup>	2	

AZLI: Aztreonam lysine; CAZ: ceftazidime; COL: Sodium colistimethate; GEN: Gentamicin; TOB: Tobramycin. C: Concomitant administration. S: Sequential administration. U: Unknown administration. \*Refers only to the intravenous formulation of the antibiotic.

**Table 4.** Prevalence of other non-antibiotic therapies

Therapy	No. patients (%)
Hypertonic saline <sup>A</sup>	204 (60)
Dornase $\alpha^B$	106 (32)
Bronchodilators <sup>C*</sup>	173 (55)
Inhaled glucocorticoids <sup>C*</sup>	137 (43)
Probiotics <sup>D</sup>	76 (23)

Data available for: A: 340 patients; B: 333 patients; C: 317 patients; D: 337 patients.

\*Concomitant administration in 120 patients.


## Discussion

This study provides the first wide report about antibiotic use in the Spanish CF setting in the absence of a national patient registry. It should be stressed that our study population is older and has a more advanced disease than that reflected in the ECFS registry, with a median [IQR] age of 18 [28-11] years vs. 15 [26-7.6] years and a median [IQR] FEV<sub>1</sub> (%) of 82.5 [92.3-66] vs. 92.5 [104.7-79.2] in <18 years and of 55.6 [73-40] vs. 67.3 [82-48] in  $\geq 18$  years (see Figures 7 and 8). The rate of chronic *P. aeruginosa* colonization is also higher among our patients (46% vs. 28.6%)<sup>13</sup>. These differences might explain the higher use of D $\alpha$  and inhaled therapy when compared with the ECFS report (31% vs. 18% and 80% vs. 53%, respectively), as D $\alpha$  therapy has been traditionally reserved for patients with more advanced disease and inhaled antibiotics are mostly used for the maintenance treatment of chronically colonized *P. aeruginosa* patients<sup>3,4</sup>.


In general, the prescription rates of the different antibiotic therapies registered in this study adjust well with CF treatment guidelines, which are mainly focused in *P. aeruginosa* eradication, exacerbations and in the lung health maintenance of chronically colonized CF patients<sup>3,4,18,19</sup>. Not surprisingly, ciprofloxacin is the most common oral

drug administered, as this antibiotic is used to treat mild *P. aeruginosa* exacerbations and can be included in treatment regimens along with inhaled antibiotics for the eradication of this bacteria<sup>3,4,18,19</sup>. Levofloxacin, which has demonstrated antipseudomonal activity, is also largely used in our country.

Intravenous antibiotic regimens were also common in our patients in parallel with their high rates of chronic *P. aeruginosa* colonization. In fact, the most common intravenous agents are antipseudomonal  $\beta$ -lactams (meropenem, ceftazidime and piperacillin-tazobactam) and tobramycin, which are normally administered in combination for the treatment of severe *P. aeruginosa* exacerbations<sup>3,19</sup>. Sodium colistimethate, which is administered continuously twice a day, and tobramycin and aztreonam lysine, which are administered twice and thrice a day respectively in alternating on/off cycles of 28 days, are currently the only approved inhaled medications for maintenance and eradication therapies in chronically-colonized *P. aeruginosa* CF patients<sup>3</sup>. The majority of our patients received only one of these antibiotics in a one-year period, thus, following the indications for *P. aeruginosa* maintenance treatment<sup>3,4</sup>. However, one of the most interesting results of this work is the relatively common use of more than one inhaled antibiotic given in a rotational scheme of 28 days. This maintenance strategy, which has been recently introduced in the Spanish consensus guidelines for patients with poor response to standard schemes, has recently been proved to be safe and may provide an additional clinical benefit to CF patients when compared with the recommended intermittent use of inhaled therapy<sup>3,20</sup>. Continuous rotational treatment may also prolong the lifespan of inhaled therapies by preventing the emergence of antibiotic resistance among *P. aeruginosa* strains<sup>8</sup>. This complexity in the treatment strategies for chronically colonized *P. aeruginosa* patients is also reflected in Figure 4, in which it is evident that combination strategies are more common in patients colonized by *P. aeruginosa*.



**Figure 7.** Boxplot analysis of the age of the patients included in the European patient registry (ECFS) and in our study (MULT). Median values are represented as black lines. Percentiles 75 and 25 are the top and the bottom of the colored boxes.



**Figure 8.** Boxplot analysis of the pulmonary function (FEV<sub>1</sub>) of the patients included in the European patient registry (ECFS) and in our study (MULT) stratified by their age. Median values are represented as black lines. Percentiles 75 and 25 are the top and the bottom of the colored boxes.

Another important finding of the study is the relatively high number of patients treated with intravenous formulated antibiotics using the inhaled route. This finding reflects clinicians' necessity of treating pathogens other than *P. aeruginosa* in CF patients, either as a maintenance therapy or as part of eradication or exacerbation regimes. The problem is that, even when virtually every antibiotic could be used by this route, non-specific inhaled preparations administered by non-adequate devices and conditions could lead to a worse toleration of the therapy and to the achievement of fewer antibiotic concentrations in the lung<sup>21,22</sup>. Although some new inhaled formulations of levofloxacin and vancomycin are now being tested in CF-patients<sup>23,24</sup>, more clinical trials are needed to assess the safety and efficacy of new inhaled antibiotics against CF pathogens as MRSA, BCC or NTM. These data would permit the inclusion of new recommendations against these pathogens in CF treatment guidelines.

Even though the prevalence of MRSA is not so high in our country (around 11%)<sup>14</sup>, it is an important CF pathogen associated with increased morbidity and mortality among colonized CF-patients<sup>25</sup>. The most frequently prescribed oral agents among 46 patients in our study with any record of MRSA isolation in 2013 were trimethoprim-sulfamethoxazole (n=20) and linezolid (n=17), and the treatment periods allowed us to infer that they were used to treat MRSA exacerbations. Although there are no consensus treatment guidelines for MRSA exacerbations, this is in line with general recommendations that identified linezolid as a preferred first-line treatment option over intravenous vancomycin or teicoplanin due to its lack of nephrotoxic effects, especially for patients treated with aminoglycosides<sup>2</sup>. In fact, few patients received intravenous vancomycin (n=4) or teicoplanin (n=3), which were probably used to treat severe exacerbations. The wide use of trimethoprim-sulfamethoxazole to treat mild MRSA exacerbations is explained by its oral bioavailability, its favorable lung penetration and activity against MRSA and other CF pathogens as BCC or *Stenotrophomonas maltophilia*. However, it could also select *S. aureus* Small Colony Variants (SCVs) which are associated with worse course of the disease<sup>2,26</sup>. There are no consensus guidelines referring to continuous maintenance treatment against MRSA. However, we identified, 5 patients receiving continuous inhaled vancomycin which reflects, as mentioned above, the effort of clinicians to improve the conditions of their patients using any available option. Four patients received inhaled vancomycin in short cycles combined with oral regimens containing rifampicin with fusidic acid and/or trimethoprim-sulfamethoxazole or linezolid. This was identified as MRSA eradication attempts as recommended in the UK CF guidelines and in other clinical reports<sup>25,27,28</sup>.

On the other hand, BCC infections are also of concern for CF-patients due to their negative impact in lung

function deterioration, spreading potential and high intrinsic resistance to many of the available antibiotics<sup>29</sup>. However and probably due to their low prevalence in CF patients, BCC-specific recommendations about any treatment aspects (maintenance, exacerbation or eradication) are lacking in clinical guidelines, forcing clinicians to assess the treatment of each patient individually<sup>10</sup>. Treatment options used by clinicians to treat this pathogen include multiple combinations of oral (trimethoprim-sulfamethoxazole, minocycline), intravenous (meropenem, ceftazidime) or inhaled (meropenem, tobramycin) therapies<sup>10</sup>. In our study, the prescription of oral and intravenous agents to patients with any history of BCC isolation (n=40) adjusted to this trend but, surprisingly, many of them received courses of inhaled ceftazidime (n=12) rather than meropenem (n=0) and at least 3 patients were taking this drug continuously as a maintenance treatment. There is limited literature about the use of inhaled ceftazidime in CF patients and there is only one case-report in which inhaled ceftazidime was successfully used for a post-transplant eradication of a *B. cenocepacia* strain<sup>12</sup>. The efficacy of inhaled ceftazidime containing regimens should be evaluated in patients carrying BCC species due to the high use of this strategy in our country.

Finally, the treatment of pathogens like *Haemophilus influenzae*, methicillin-susceptible *S. aureus* (MSSA) or *Streptococcus pneumoniae* is reflected in the common use of other oral antibiotics, as amoxicillin-clavulanate, trimethoprim-sulfamethoxazole or cefuroxime<sup>5</sup>. Use of these antibiotics was more common among younger CF-patients (<18 years) or when no other pathogens were recovered from sputum (data not shown). Maintenance therapies with continuous amoxicillin-clavulanate and trimethoprim-sulfamethoxazole were also identified in 5 and 2 patients respectively, even though some reports relate these anti-staphylococcal antibiotics with a higher risk of *P. aeruginosa* acquisition in CF-patients<sup>25</sup>. Another interesting finding was the relative common use of inhaled ampicillin in 9 patients chronically colonized by MSSA, 8 of them receiving it continuously. This long-term use of inhaled ampicillin in CF patients has been previously reported and, although it has achieved a reduction in hospitalization rates and oral antibiotic use, it has not been able to eradicate the pathogen<sup>12,30</sup>.

This work has limitations, principally the lack of information about treatment objectives for each patient in some cases. Recovery of this information was not the main objective of the above mentioned multicenter study and was not included in its design. Therefore and even having information about dosing and duration of each drug, in many cases we were not able to ascertain if a particular treatment was used for maintenance purposes, for the eradication of a particular pathogen or for the management of an exacerbation. Despite this limitation, we obtained relevant information about how antibiotics are used in the Spanish CF context, which could

be useful for future comparative studies on this topic in our country and after publication of our national guidelines<sup>3</sup>. This information also completes that provided by the ECFS patient registry, in which only data about the use of inhaled antibiotics, anti-inflammatory macrolides, D $\alpha$ , HS and BD are provided<sup>14</sup>. Future studies on this topic will be needed in Spain to evaluate the treatment role of the new antibiotics, as inhaled levofloxacin and amikacin or intravenous ceftaroline, and the new CFTR modulators, as ivacaftor or its combination with lumacaftor.

## Acknowledgements

The authors are grateful to all the members of the GEIFQ Study Group and to all cystic fibrosis Spanish patients that agreed to participate in this multicenter study. The GEIFQ Study Group (Grupo Español para el Estudio de la Colonización/Infección Broncopulmonar en Fibrosis Quística): **Amparó Solé** and **Isidoro Cortell** (Hospital Universitario y Politécnico la Fe, Valencia, Spain); **Oscar Asensio** (Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain); **Gloria García** and **María Teresa Martínez** (Hospital 12 de Octubre, Madrid, Spain); **María Cols** (Hospital San Joan de Déu, Barcelona, Spain); **Antonio Salcedo** (Hospital Niño Jesús/Gregorio Marañón, Madrid, Spain); **Carlos Vázquez** and **Félix Baranda** (Hospital Universitario Cruces, Barakaldo, Vizcaya, Spain); **Rosa Girón** (Hospital de la Princesa, Madrid, Spain); **Esther Quintana** and **Isabel Delgado** (Hospital Universitario Virgen del Rocío, Sevilla, Spain); **María Ángeles de Miguel** and **Marta García** (Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain); **Concepción Oliva** (Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain); **María Concepción Prados** and **María Isabel Barrio** (Hospital Universitario la Paz, Madrid, Spain); **María Dolores Pastor** (Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain); **Casilda Oliveira** (Hospital Regional Universitario de Málaga, Málaga, Spain); **Javier de Gracia** and **Antonio Álvarez** (Hospital Vall d'Hebrón, Barcelona, Spain); **Amparo Escribano** and **Silvia Castillo** (Hospital Clínico Universitario de Valencia and Universidad de Valencia, Valencia, Spain); **Joan Figuerola**, **Bernat Togores**, **Antonio Oliver** and **Carla López** (Hospital Universitari Son Espases, Palma de Mallorca, Spain); **Juan de Dios Caballero**, **Marta Tato**, **Luis Máiz**, **Lucrecia Suárez** and **Rafael Cantón** (Hospital Universitario Ramón y Cajal, Madrid, Spain).

## Conflicts of interests

Dr. Canton has participated in educational activities sponsored by Gilead (regarding cystic fibrosis research) and from MSD (regarding other fields of study). He also reported grants from MSD and AstraZeneca outside the submitted work.

## Ethical approval

This multicenter study was approved by each hospital's ethical committee. Written informed consent was also provided by all included patients and/or by their parents or legal guardians.

## Funding

Research in the Microbiology Department of Ramón y Cajal Hospital (Madrid, Spain) in the field of cystic fibrosis are funded by the Instituto de Salud Carlos III of Spain, Plan Estatal de I+D+I 2013-2016 (grants PI12-00734, PI13-00205 and PI15-00466), and co-financed by the European Development Regional Fund "A Way to Achieve Europe program" (ERDF); Spanish Network for Research in Infectious Diseases grant REIPI RD12-0015/0004. JdeD Caballero is supported with a research contract from Instituto de Salud Carlos III of Spain (Rio Hortega program, ref. CM14-00059).

## References

- Davis PB. Cystic fibrosis since 1938. *Am J Respir Crit Care Med*. 2006;173(5):475–82.
- Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, *et al*. Antibiotic management of lung infections in cystic fibrosis: I. The microbiome, methicillin-resistant *Staphylococcus aureus*, gram-negative bacteria, and multiple infections. *Ann Am Thorac Soc*. 2014;11(7):1120–9.
- Cantón R, Máiz L, Escribano A, Oliveira C, Oliver A, Gartner S, *et al*. Spanish consensus on the prevention and treatment of *Pseudomonas aeruginosa* bronchial infections in cystic fibrosis patients. *Arch Bronconeumol*. 2015;51(3):140–50.
- Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjilias D, Hoag JB, *et al*. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. *Am J Respir Crit Care Med*. 2013;187(7):680–9.
- Bhatt JM. Treatment of pulmonary exacerbations in cystic fibrosis. *Eur Respir Rev*. 2013;22(129):205–16.
- Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, *et al*. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. *J Cyst Fibros*. 2011;10(1):54–61.
- Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, *et al*. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. *Pediatr Pulmonol*. 2010;45(11):1121–34.
- VanDevanter DR, Ballmann M, Flume PA. Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. *Respir Med*. 2011;105(Suppl2):S18–23.
- Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Stuart Elborn J, LiPuma JJ, *et al*. Antibiotic management of lung infections in cystic fibrosis: II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. *Ann Am Thorac Soc*. 2014;11(8):1298–306.
- Gautam V, Shafiq N, Singh M, Ray P, Singhal L, Jaiswal NP, *et al*. Clinical and in vitro evidence for the antimicrobial therapy in *Burkholderia cepacia* complex infections. *Expert Rev Anti Infect Ther*. 2015;13(5):629–63.
- Dasenbrook EC, Konstan MW, VanDevanter DR. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. *J Cyst Fibros*. 2015;14(3):370–5.

12. Falagas ME, Trigkidis KK, Vardakas KZ. Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review. *Int J Antimicrob Agents* 2015;45(3):221–33.
13. European Cystic Fibrosis Society. Patient Registry Annual Data Report 2013. Published in February 2016. Available at: <https://www.ecfs.eu/content/ecfs-patient-registry>
14. de Dios Caballero J, del Campo R, Royuela A, Solé A, Máiz L, Oliveira C, et al. Bronchopulmonary infection-colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study. *J Cyst Fibros*. 2016;15(3):357-65.
15. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic *Pseudomonas aeruginosa* infection in cystic fibrosis patients. *J Cyst Fibros*. 2003;2(1):29–34.
16. Micalef L, Rodgers P. euler APE: Drawing area-proportional 3-Venn diagrams using ellipses. *PLoS One* 2014;9(7):e101717.
17. Rodgers P, Stapleton G, Chapman P. Visualizing Sets with Linear Diagrams. *ACM Trans Comput Interact*. 2015;22(6):27.
18. Mogayzel PJ, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, et al. Cystic fibrosis foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial *Pseudomonas aeruginosa* infection. *Ann Am Thorac Soc*. 2014;11(10):1640–50.
19. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations. *Am J Respir Crit Care Med*. 2009;180(9):802–8.
20. Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, et al. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. *J Cyst Fibros*. 2016;15(6):809-15.
21. Agent P, Parrott H. Inhaled therapy in cystic fibrosis: agents, devices and regimens. *Breathe (Sheffield, England)* 2015;11(2):110–8.
22. Allothman GA, Alsaadi MM, Ho BL, Ho SL, Dupuis A, Corey M, et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. *Chest* 2002;122(3):930–4.
23. Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, et al. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. *J Cyst Fibros*. 2016;15(4):495–502.
24. Savara Inc. Efficacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic fibrosis patients. *Clinicaltrials.Gov*. NLM identifier: NCT01746095. Bethesda, MD: National Library of Medicine (US). 2012 [accessed 2016 Aug 23]. Available from: <http://clinicaltrials.Gov/ct2/show/nct01746095>
25. Goss CH, Muhlebach MS. Review: *Staphylococcus aureus* and MRSA in cystic fibrosis. *J Cyst Fibros*. 2011;10(5):298–306.
26. Fusco NM, Toussaint KA, Prescott WA Jr. Antibiotic management of methicillin-resistant *Staphylococcus aureus*-associated acute pulmonary exacerbations in cystic fibrosis. *Ann Pharmacother*. 2015;49(4):458-68.
27. Doe SJ, McSorley A, Isalska B, Kearns AM, Bright-Thomas R, Brennan AL, et al. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant *Staphylococcus aureus* at large cystic fibrosis centres. *J Cyst Fibros*. 2010;9(2):104–9.
28. Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group. 3rd Edn. London, Cystic Fibrosis Trust, 2009.
29. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon *Burkholderia cepacia* complex. *Nat Rev Microbiol*. 2005;3(2):144–56.
30. Máiz L, Del Campo R, Castro M, Gutiérrez D, Girón R, Cantón Moreno R. Maintenance treatment with inhaled ampicillin in patients with cystic fibrosis and lung infection due to methicillin-sensitive *Staphylococcus aureus*. *Arch Bronconeumol*. 2012;48(10):384.